"Furthermore, although the reviewed studies have consistently shown the cardioprotective effects of SGLT2 inhibitors against cancer treatment–related cardiotoxicity in tumor-free models, none has yet concurrently demonstrated the cardioprotective and the anticancer effects of SGLT2 inhibitors in tumor-bearing model"
Definitely a space to watch, the SGLT2s are ubiquitous in cardiorenal disease and form part of the fundamental 4 pillars of heart failure treatments along with the ARNIs, beta-blockers and MRAs. They will get great physician buy-in if they can demonstrate cardioprotection in an RCT.
Of course the holy-grail is cardioprotection AND anti-cancer synergy which is yet to be proven in SGLT2s but this could pose a threat to bisantrene if proven.
Gret find @HeyLine
- Forums
- ASX - By Stock
- RAC
- Cardioprotection thread
Cardioprotection thread, page-557
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.70 |
Change
-0.140(7.61%) |
Mkt cap ! $289.4M |
Open | High | Low | Value | Volume |
$1.88 | $1.89 | $1.70 | $456.4K | 259.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.69 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 8662 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.690 |
2 | 6661 | 1.685 |
1 | 727 | 1.680 |
1 | 5970 | 1.675 |
1 | 727 | 1.670 |
Price($) | Vol. | No. |
---|---|---|
1.700 | 8662 | 1 |
1.730 | 943 | 1 |
1.740 | 500 | 1 |
1.745 | 727 | 1 |
1.755 | 727 | 1 |
Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |